Vivos Therapeutics, Inc.: 10-Q filed 2023-11-14
What Vivos Therapeutics, Inc. reported in its quarterly report filed 2023-11-14 (fiscal Q3 2023): 46 published measures, 129 facts as tagged in accession 0001493152-23-041150.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-11-14
- Fiscal period
- fiscal Q3 2023
- Accession
- 0001493152-23-041150 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Vivos Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 10,317,000 | USD | |
| At 2022-12-31 | 13,720,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 10,271,000 | USD | |
| At 2022-12-31 | 8,919,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 46,000 | USD | |
| At 2023-06-30 | 2,106,000 | USD | |
| At 2023-03-31 | 6,993,000 | USD | |
| At 2022-12-31 | 4,801,000 | USD | |
| At 2022-09-30 | 9,855,000 | USD | |
| At 2022-06-30 | 14,839,000 | USD | |
| At 2022-03-31 | 21,039,000 | USD | |
| At 2021-12-31 | 25,539,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 988,000 | USD | |
| At 2022-12-31 | 3,519,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -2,093,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -9,324,000 | USD | 273 |
| 2023-04-01 to 2023-06-30 | -5,528,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -1,703,000 | USD | 90 |
| 2022-07-01 to 2022-09-30 | -5,434,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -17,756,000 | USD | 273 |
| 2022-04-01 to 2022-06-30 | -6,992,000 | USD | 91 |
| 2022-01-01 to 2022-03-31 | -5,331,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -9,198,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -16,587,000 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 638,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 724,000 | USD | 273 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 3,301,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 10,553,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 4,246,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 12,074,000 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 7,355,000 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -688,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -724,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -88,792,000 | USD | |
| At 2022-12-31 | -79,468,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 1,197,258 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 1,152,607 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 849,446 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 849,446 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 1,197,258 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 1,152,607 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 849,446 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 849,446 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -1.75 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -8.09 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -6.4 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -20.9 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -1.75 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -8.09 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -6.4 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -20.9 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 3,283,000 | USD | |
| At 2022-12-31 | 3,082,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 954,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 1,621,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -3,489,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -13,012,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -5,407,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -18,968,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,985,000 | USD | |
| At 2022-12-31 | 5,424,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 7,167,000 | USD | |
| At 2022-12-31 | 6,813,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,528,000 | USD | |
| At 2022-12-31 | 1,411,000 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 2,843,000 | USD | |
| At 2022-12-31 | 2,843,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 433,000 | USD | |
| At 2022-12-31 | 302,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 228,000 | USD | |
| At 2022-12-31 | 457,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 5,387,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 19,345,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 7,903,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 26,603,000 | USD | 273 |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 1,898,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 6,333,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 2,496,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 7,635,000 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 100,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 200,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 100,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 200,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,197,258 | shares | |
| At 2022-12-31 | 920,592 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 88,835,000 | USD | |
| At 2022-12-31 | 84,267,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,466,000 | USD | |
| At 2022-12-31 | 1,695,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 2,104,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 5,473,000 | USD | |
| At 2022-12-31 | 4,835,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 2,190,000 | USD | |
| At 2022-12-31 | 1,753,000 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 433,000 | USD | |
| At 2022-12-31 | 302,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,922,000 | USD | |
| At 2022-12-31 | 1,912,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 769,000 | USD | |
| At 2022-12-31 | 1,448,000 | USD |
Current contract liabilities
Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 2,373,000 | USD | |
| At 2022-12-31 | 2,926,000 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -2,093,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -9,324,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -5,434,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -17,756,000 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 4,596,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 17,012,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 6,622,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 22,118,000 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 200,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 500,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 200,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 300,000 | USD | 273 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 472,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 500,000 | USD | 273 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 100,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 100,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 100,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 100,000 | USD | 273 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -53,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -198,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -36,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -152,000 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | 2,000 | USD | 273 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -229,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -337,000 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 118,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -276,000 | USD | 273 |
Inspect the source
- Entity
- Vivos Therapeutics, Inc. / CIK 0001716166
- Captured
- 2026-09-21T17:26:59.972Z
- SEC response SHA-256
efd07425d40bc920d359ff76b1334c560a1babfb4f9db602e6a12742d0495542
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001716166.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))